Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847892 | 0.86 | ACKR3 (0.44) | ACKR3CYP1A2ALDH1A1CHRM3TERT | |
| SCHEMBL15745587 | 0.85 | POLB (0.49) | ACKR3CYP1A2ALDH1A1CHRM3CHRNB2 | |
| SCHEMBL12847891 | 0.85 | ACKR3 (0.38) | ACKR3CYP1A2ALDH1A1CHRM3CHRNB2 | |
| SCHEMBL10244794 | 0.82 | CHRNB2 (0.41) | CYP1A2ALDH1A1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL16328043 | 0.80 | CYP1A2 (0.47) | ACKR3CYP1A2ALDH1A1CHRNB2CHRNA5 | |
| SCHEMBL19708766 | 0.80 | CYP1A2 (0.47) | CYP1A2ALDH1A1CHRM3CHRNB2CHRNA5 | |
| SCHEMBL19544406 | 0.80 | CYP1A2 (0.47) | ACKR3CYP1A2ALDH1A1CHRNB2CHRNA5 | |
| SCHEMBL15745596 | 0.80 | MAPT (0.49) | ACKR3CYP1A2ALDH1A1TERT | |
| SCHEMBL19544407 | 0.79 | CYP1A2 (0.46) | ACKR3CYP1A2ALDH1A1CHRM3CHRNB2 | |
| SCHEMBL18688759 | 0.75 | CYP1A2 (0.55) | CYP1A2CHRM3CHRNB2CHRNA5CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239443-A1 | Preparation Method for Tyrosine Kinase Inhibitor and Intermediate Thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239443-A1 | Preparation Method for Tyrosine Kinase Inhibitor and Intermediate Thereof | ABL1, ABL2, LYN | ACKR3 3432/4885CYP1A2 1057/4885ALDH1A1 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.